Whitehawk Therapeutics, Inc. (WHWK)
| Market Cap | 187.83M +165.9% |
| Revenue (ttm) | n/a -72.5% |
| Net Income | -115.81M |
| EPS | -1.67 |
| Shares Out | 49.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 204,283 |
| Open | 3.940 |
| Previous Close | 3.970 |
| Day's Range | 3.670 - 4.020 |
| 52-Week Range | 1.550 - 4.480 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+97.37%) |
| Earnings Date | May 7, 2026 |
About WHWK
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Financial Performance
In 2025, Whitehawk Therapeutics's revenue was $7.15 million, a decrease of -72.50% compared to the previous year's $25.98 million. Losses were -$20.60 million, -67.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for WHWK stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 97.37% from the latest price.
News
Whitehawk Therapeutics price target raised to $7 from $6 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on Whitehawk Therapeutics (WHWK) to $7 from $6 and keeps an Outperform rating on the shares after the company provided Q1…
Whitehawk Therapeutics reports Q1 EPS (32c), consensus (33c)
Reports Q1 revenue $0 vs. $7.14M last year. “This quarter reflects continued progress across our pipeline as we advance Phase 1 dose-escalation studies for HWK-007 and HWK-016, with a third…
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 Cash, cash equivalents and short-term investments balance of $123.0 million as of March 31, 2...
Whitehawk announces presentation of new preclinical data across ADC portfolio
Whitehawk Therapeutics (WHWK) announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research, AACR, Annual Meeting 2026, taking place April...
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across vari...
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology...
Whitehawk Therapeutics management to meet with Oppenheimer
Meeting to be held in San Diego on April 21 hosted by Oppenheimer.
Whitehawk Therapeutics initiated with an Outperform at Citizens
Citizens analyst Reni Benjamin initiated coverage of Whitehawk Therapeutics (WHWK) with an Outperform rating and $8 price target Whitehawk is advancing three antibody-drug conjugates “against clinical...
Whitehawk Therapeutics presents analysis of MUC16 at SGO
Whitehawk Therapeutics (WHWK) presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 with a next-generation ADC for the treatment of ovarian and ...
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes ...
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology...
Whitehawk Therapeutics reports Q4 EPS (34c) vs. (67c) last year
Reports Q4 revenue $0, consensus $20M. Cash, cash equivalents and short-term investments as of December 31, 2025, were $145.7M vs. $47.2M as of December 31, 2024. Cash is anticipated to…
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016 HWK-206 on track for planned IND submission in mid-2026 and Phase 1 start in Q...
Whitehawk Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Three ADC programs are advancing, each targeting high-value cancer antigens with a proprietary, safer linker-payload system. Two programs are in clinical trials, with data expected in early 2027, and a third will enter the clinic in Q3. Cash reserves support operations into 2028.
Whitehawk Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing three next-generation ADC programs with a unique, highly stable platform designed to improve efficacy and safety across multiple cancer types. Early clinical data for two programs are expected in 2027, with a third entering trials in 2026, all supported by strong capital efficiency and a focus on best-in-class outcomes.
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology ...
Whitehawk Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Three ADC assets are advancing through clinical development, with two in Phase 1 and a third entering trials in Q3 2025. The platform offers improved potency, safety, and stability, with initial clinical data expected in H1 2027 and preclinical data releases planned for spring 2026.
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology ...
Whitehawk Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Whitehawk Therapeutics (WHWK) with an Outperform rating and $6 price target The firm sees Whitehawk as “a promising early player in the ADC space” and expects…
Whitehawk Therapeutics says FDA clears IND application for HWK-007
Whitehawk Therapeutics (WHWK) announced that the U.S. FDA has cleared the Investigational New Drug application for HWK-007, its PTK7-targeted ADC. Whitehawk’s Phase 1 trial for HWK-007 is now actively...
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 IND submitted mid-December 2025 for MUC16-targeted ADC HWK-016, anticipated Phase 1 start this quarter Initial...
Whitehawk Therapeutics initiated with a Buy at JonesResearch
JonesResearch analyst Soumit Roy initiated coverage of Whitehawk Therapeutics (WHWK) with a Buy rating and $7 price target The company is positioned to achieve “potentially best-in-class designation” ...
Whitehawk Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Three differentiated ADC programs are advancing to the clinic, targeting PTK7, MUC16, and SEZ6, with INDs planned by 2026 and initial clinical data expected in Q1 2027. The company is well-funded through early 2028 and aims to demonstrate best-in-class efficacy and safety across multiple solid tumor indications.
Whitehawk Therapeutics appoints Dugan as Chief Medical Officer
Whitehawk Therapeutics (WHWK) announced the appointment of Margaret Dugan, MD, as Chief Medical Officer, CMO. Dr. Dugan brings more than 30 years of global oncology drug development experience, with e...
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J. , Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an ...